1965291-08-0
Chemical Structure
Ibrexafungerp citrate
Synonym(s): MK 3118 citrate; SCY-078 citrate
- CAS No.: 1965291-08-0
- Formula:C50H75N5O11
- Molecular Weight:922.16
IUPAC Name: (1S,2R,3R,4aR,6aS,7R,8R,10aR,10bR,12aR)-2-((R)-2-amino-2,3,3-trimethylbutoxy)-1,6a,8,10a-tetramethyl-8-((R)-3-methylbutan-2-yl)-3-(5-(pyridin-4-yl)-1H-1,2,4-triazol-1-yl)-1,3,4,6,6a,7,8,9,10,10a,10b,11,12,12a-tetradecahydro-2H-1,4a-(methanooxymethano)chrysene-7-carboxylic acid compound with 2-hydroxypropane-1,2,3-tricarboxylic acid (1:1)
InChIKey: WKIRTJACGBEXBZ-FQGZCCSZSA-N
SMILES: C[C@@]12[C@@](CC3)([H])[C@@](C[C@](N4C(C5=CC=NC=C5)=NC=N4)([H])[C@@H]1OC[C@](C)(N)C(C)(C)C)(COC2)C([C@@]3([H])[C@]6(CC[C@]7(C)[C@H](C)C(C)C)C)=CC[C@]6([C@@H]7C(O)=O)C.OC(CC(C(O)=O)(O)CC(O)=O)=O
Biological Activity: Ibrexafungerp citrate (MK 3118 citrate) is an orally active β-1,3-glucan synthesis inhibitor, with potential antifungal activity. Ibrexafungerp citrate is an investigational agent for the treatment of Candida and Aspergillus infections[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ibrexafungerp citrate | 99.38% | Ibrexafungerp citrate (MK 3118 citrate) is an orally active β-1,3-glucan synthesis inhibitor, with potential antifungal activity. Ibrexafungerp citrate is an investigational agent for the treatment of Candida and Aspergillus infections. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ibrexafungerp citrate (Standard) | Ibrexafungerp citrate (Standard) (MK 3118 citrate (Standard)) is the analytical standard of Ibrexafungerp (citrate) (HY-107126A). This product is intended for research and analytical applications. Ibrexafungerp citrate (MK 3118 citrate) is an orally active β-1,3-glucan synthesis inhibitor, with potential antifungal activity. Ibrexafungerp citrate is an investigational agent for the treatment of Candida and Aspergillus infections. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
